Skip to content
RecruitingN/A

Ketamine Treatment Plans for Chronic Conditions

NCT06038409 · RIVER Foundation

Recruiting
Status
Accepting participants
Not applicable
Phase
500
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

A study aimed to assess the efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the study plan of those with chronic conditions who are receiving ketamine.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Ketamine route of use acceptability.

    Measured over through study completion, an average of 1 year

  • Mental Health PHQ9

    Measured over through study completion, an average of 1 year

  • Mental Health GAD7

    Measured over through study completion, an average of 1 year

  • Mental Health PCL5

    Measured over through study completion, an average of 1 year

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: Must have an identifiable chronic condition. Exclusion Criteria: Healthy population

Where

1 study site

FacilityCityRegionCountry
RIVER TelehealthHelenaMontanaUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06038409 on ClinicalTrials.gov →

Last updated in the registry 2024-11-26. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits